AUA 2018: How Surgical Factors Influence Renal Functional Preservation in Healthy and "At-Risk" Kidneys after Partial Nephrectomy
San Francisco, CA USA (UroToday.com) Dr. Dagenais of the Cleveland Clinic presented a moderated poster of their study looking at the incidence and predictors of chronic kidney disease (CKD) upstaging after partial nephrectomy.
The authors retrospectively reviewed the charts of 778 patients from their single institutional database of patients who underwent partial nephrectomy. Of these patients, 634 had healthy, normal kidneys and 144 either had CKD or were at risk for developing CKD. “At risk” was defined as those patients with hypertension, diabetes, and/or a smoking history. Upstaging of CKD was determined using the estimated glomerular filtration rate (eGFR) calculated using the MDRD equation and postoperative creatinine values between 3 to 12 months.
AUA 2018: Distribution of M0 Renal Cell Carcinoma Metastases Stratified by Pathologic Nodal Status
San Francisco, CA USA (UroToday.com) David Y Yang, from the Mayo Clinic, Rochester, MN presented an evaluation of the timing and anatomic distribution of first metastasis in treated RCC patients stratified by nodal status. Yang began by identifying that brain metastases are frequently diagnosed among patients with renal cell carcinoma (RCC) and are associated with a poor prognosis. These patients have historically been excluded from clinical trials and aggressive treatment regimens. There are limited guidelines on screening and surveillance for brain involvement.
AUA 2018: Carcinomas Of The Renal Medulla: A Comprehensive Genomic Profiling (Cgp) Study
San Francisco, CA USA (UroToday.com) Stephanie Gleicher, MD, urology resident at the State University of New York Upstate Medical University, presented on the genomic profiling (Cgp) of renal medullar carcinoma (RMC) and collecting duct carcinoma (CDC). The author opened by describing RMC and CDC as being extremely rare but aggressive subtypes of renal cancer, making up less than 1% of renal cancer cases, but also being associate with high probability of metastasis. Current treatment guidelines of both RMC and CDC are primarily chemotherapy, while preforming a debunking nephrectomy in conjunction to chemotherapy has shown to increase survival rates.
AUA 2018: Effect of Ketogenic Diet on the Clear Cell Renal Cell Carcinoma Cell Growth
San Francisco, CA USA (UroToday.com) In recent years, lifestyle intervention via diet and exercise has become an increasingly popular prevention and therapy mechanism for patients suffering from diseases known to be exacerbated by metabolic syndromes. In this regard, clear cell renal cell carcinoma (ccRCC) has been of no exception.
AUA 2018: Somatic Mutation in Mitochrondrial DNA Predicts Postoperative Recurrence in Renal Cell Carcinoma.
San Francisco, CA USA (UroToday.com) While it is well-known that DNA mutations and errors in replication increase risk of cancerous cell growth, it is less-known that mutations in mitochondrial DNA (mtDNA) may be a similarly-important influencer. Even further, given that mtDNA mutations occur at a 10-fold higher rate than nuclear DNA, early detection can pose significant advantage in predicting disease progression and postoperative recurrence of RCC.
AUA 2018: Percutaneous Cryoablation of Renal Tumors in Solitary Kidney: Results From an Italian Multicentric Study
San Francisco, CA USA (UroToday.com) Gaetano Chiapparrone from the Urologic Clinic of Azienda Sanitaria Universitaria Integrata di Trieste delivered a podium on their study assessing outcomes when using percutaneous cryoablation (PCA) in patients with a solitary kidney.
AUA 2018: Safety and Efficacy of Percutaneous US and CT Guided Microwave Ablation of T1a and T1b Renal tumors
San Francisco, CA USA (UroToday.com) Sepideh Shakeri of the Department of Radiology at the University of California Los Angeles delivered a podium on their study assessing the safety and efficacy of image-guided microwave ablation (MWA) in biopsy-proven renal cell carcinoma (RCC).